Key Points
- NewAmsterdam Pharma CAO Louise Frederika Kooij sold 65,000 shares on May 26 at an average price of $35.69, for total proceeds of about $2.32 million. After the sale, she retained 24,353 shares, reducing her ownership by 72.75%.
- The stock rose 1.2% to $36.56 in Thursday trading and has a market value of about $4.27 billion. It remains well below its 52-week high of $42.21 but above its low of $16.78.
- Analysts are generally constructive on NAMS, with an average rating of “Moderate Buy” and a consensus price target of $48.00. Recent coverage included multiple Buy/Strong Buy ratings, though one analyst maintained a Sell rating.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company's stock, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
NewAmsterdam Pharma Trading Up 1.2%
NewAmsterdam Pharma stock opened at $36.56 on Thursday. The stock has a market cap of $4.27 billion, a P/E ratio of -20.42 and a beta of 0.02. The company has a fifty day simple moving average of $33.16 and a 200-day simple moving average of $34.21. NewAmsterdam Pharma Company N.V. has a 12-month low of $16.78 and a 12-month high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a "buy" rating and a $57.00 price target on the stock. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. HC Wainwright upgraded shares of NewAmsterdam Pharma to a "strong-buy" rating in a research note on Thursday, February 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $48.00.
View Our Latest Research Report on NewAmsterdam Pharma
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of NAMS. Farther Finance Advisors LLC boosted its stake in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock worth $25,000 after buying an additional 708 shares during the period. Wells Fargo & Company MN increased its position in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock valued at $32,000 after acquiring an additional 300 shares during the period. KBC Group NV acquired a new position in NewAmsterdam Pharma in the 1st quarter valued at about $37,000. Navalign LLC acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at about $46,000. Finally, AdvisorNet Financial Inc acquired a new position in NewAmsterdam Pharma in the 1st quarter valued at about $82,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
